The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

If you have the condition and are considering your treatment options, you may be wondering whether this GLP-1 receptor agonist is the right choice for you.Available clinical trial data shows that ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

They improve insulin sensitivity, reduce hunger signals and help people feel fuller for longer. They don’t magically repair ...